Candace Haddox, MD
Medical Oncology · Boston, MANPI 1508246018
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,750 of the $7,384 with a category attached, or 64.3%. Deciphera Pharmaceuticals Inc. accounts for 67.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $4,985 and has fallen 56.5% since, to $2,168 in 2025.
Across 16 payments — averaging $461.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Deciphera Pharmaceuticals Inc.$5K
- Springworks Therapeutics, Inc.$2K
- AstraZeneca$160
- Daiichi Sankyo Inc.$74
- Aadi Bioscience, Inc.$40
Across 25 payments — averaging $38,502 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aadi Bioscience, Inc.$957K
- Genentech, Inc.$5K
- Merck Kgaa$624
What the payments were for
- Consulting fees$2,16029%
- Speaking & faculty fees$4,75064%
- Food & beverage$3365%
- Education$1382%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Deciphera Pharmaceuticals Inc. | 8 | $4,950 |
| Springworks Therapeutics, Inc. | 1 | $2,160 |
| AstraZeneca | 3 | $160 |
| Daiichi Sankyo Inc. | 3 | $74 |
| Aadi Bioscience, Inc. | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,384 in reported general payments places this provider in the 60th percentile of 308 medical oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 21 | $101,452 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Boston
- George DemetriBoston$1.6M
- Keith FlahertyBoston$932K
- Alicia MorgansBoston$690K
- Pasi Antero JanneBoston$458K
- Robert HaddadBoston$451K
- Irene GhobrialBoston$431K
- Joaquin Bellmunt MolinsBoston$415K
- Jeremy AbramsonBoston$334K
- Justin GainorBoston$324K
- Narjust FlorezBoston$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.